SIB-1508Y (SIBIA Neurosciences) is a selective alpha-4-beta-2 nicotinic acetylcholine receptor agonist. This drug is of interest in PD as nicotinic receptor stimulation augments dopamine release. A dose finding study in 77 early PD patients demonstrated no clear antiparkinsonian effect or cognitive benefit (36). Light headedness was a common dosage-related adverse event, leading to frequent dosage reductions. A maximally tolerated dosage of 10 mg daily was identified. Further plans for development of this agent are not known.
Was this article helpful?